Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-01-05
2000-11-14
Chan, Christina Y.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, C07H 2102, C07H 2104
Patent
active
061472034
ABSTRACT:
The present invention relates to disulfide-stabilized recombinant polypeptide molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the V.sub.H and V.sub.L regions of the Fv fragment. The .alpha. and .beta. chains of T cell receptors may be similarly stabilized by means described in the invention.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5132405 (1992-07-01), Huston et al.
R. Kreitman et al.: "The activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 towards human CD22+ lymphoma/leukemia xenografts in mice and fresh cells from patients." Proceedings of the American Association for Cancer Research, vol. 38, Mar. 1997, p. 28 XP002075139 USA see abstract #187.
J. De Kruif et al.: "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes." FEBS Letters, vol. 399,, No. 3, Dec. 16, 1996, pp. 232-236, XP002075140 Amsterdam, NL.
Y. Reiter et al.: "Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions." Biochemistry vol. 33, No. 18, May 10, 1994, pp. 5451-5459, XP002075141 Washington, D.C, USA.
R. Kreitman et al.: "Pseudomonas exotoxin-based imunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice." Cancer Research, vol. 53, No. 4, Feb. 15, 1993, pp. 819-825, XP002075142 Baltimore, MD, USA.
C-T. Kuan et al. "Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation." Biochemistry, vol. 35, No. 9, Mar. 5, 1996, pp. 2872-2877, XP002075143 Washington, DC, USA.
V. Rajagopal et al.: "A form of anti-Tac(Fv) which is both single-chain and disulfide-stabilized for imaging CD25+ tumors." Proceedings of the American Association for Cancer Research, vol. 8, Mar. 1997, p. 27 XP002075144 USA see abstract #180.
D. Luo et al.: "V1-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions." Journal of Biochemistry, vol. 118, No. 4, Oct. 1, 1995, pp. 825-831, XP002075145 Tokyo, Japan.
M. Rordigues et al.: "Development of a humanized disulfide-stabilized anti-p185HER2 Fv-betalactamase fusion protein for activation of a cephalosporin doxorubicin prodrug." Cancer Research, vol. 55, No. 1, Jan. 1, 1995, pp. 63-70, XP002075146 Baltimore, MD, USA.
E. Mansfield et al.: "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies." Bioconjugate Chemistry, vol. 7, No. 5, Sep. 1996, pp. 557-563, XP002075147 Washington, DC, USA.
E. Mansfield et al.: "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors." Blood, vol. 90, No. 5, Sep. 1, 1997, pp. 2020-2026, XP002075148 New York, NY, USA.
Batra et al., Proc. Natl. Acad. Sci. USA, 89:5967-5871 (1992).
Bird et al., Science, 242:423-426 (1988).
Brinkmann et al., J. Immunology, 150:2774-2782 (1993).
Brinkmann et al., Proc. Natl. Acad. Sci., 90:7538-7542 (Aug. 1993).
Brinkmann et al., Proc. Natl. Acad. Sci., 88:8616-8620 (Oct. 1991).
Buchner et al., Anal. Biochem., 205:263-270 (1992).
Cumber et al., J. Immunology, 149(1) :120-126 (Jul. 1, 1992).
Dillman, Ann. Internal. Med., 111:592-600 (1989).
Glockshuber et al., Biochemistry, 29:1362-1367 (1990).
Glockshuber et al., Biochemistry, 31(5) :1270-1279 (Feb. 11, 1992).
Harris et al. TIBTECH, 11:42-42 (1993).
Huston et al., Proc. Natl. Acad. Sci. USA, 85:5879-5883 (1988).
Hird et al., Genes and Cancer (1990) chapter 17 pp. 183-189.
Kasprzyk et al., Cancer Research, 53:2771-2776 (May 15, 1992).
Kuruez et al., Proc. Natl. Acad. Sci., 90:3830-3834 (May 1993).
Osband et al., Immunotherapy, 11(6) :193-195 (1990).
Pantoliano et al., Biochemistry, 30:10117-10125 (1991).
Reiter et al., Biochemistry 33:5451-5459 (May 10, 1994).
Reiter et al., J. Biological Chemistry, 269(28) :18327-1833 (Jul. 15, 1994).
Stemmer et al., Biotechniques, 14(2) :256-265 (1993).
Pack et al., Biochemistry, 31:1579-1584 (1992).
Waldmann, Science, 252:1657-1662 (1991).
Brinkmann Ulrich
Jung Sun-Hee
Lee Byungkook
Pastan Ira H.
Chan Christina Y.
Ewoldt Gerald R.
The United States of America as represented by the Department of
LandOfFree
Recombinant disulfide-stabilized polypeptide fragments having bi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant disulfide-stabilized polypeptide fragments having bi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant disulfide-stabilized polypeptide fragments having bi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2066551